DBV Technologies (FRA:DBV) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:DBV DBV Technologies SA FRA:DBV
27 GF Score
Price €2.77
! 1 Warning Sign
View Full Analysis

What is DBV Technologies OCF Margin %?

DBV Technologies FRA:DBV -1.00% 27 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:DBV with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, DBV Technologies ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. DBV Technologies's Cash Flow from Operations for the three months ended in Mar. 2026 was €-42.47 Mil. DBV Technologies's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, DBV Technologies's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, DBV Technologies's current OCF Yield % is -15.52%.

The historical rank and industry rank for DBV Technologies's OCF Margin % or its related term are showing as below:


FRA:DBV's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

DBV Technologies OCF Margin % Related Terms

DBV Technologies OCF Margin % Historical Data

* Premium members only.

The historical data trend for DBV Technologies's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies OCF Margin % Chart

DBV Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DBV Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:DBV
27GF Score
DBV Technologies SA FRA:DBV
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

DBV Technologies's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-103.489/0
= %

DBV Technologies's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-42.471/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
DBV Technologies (FRA:DBV) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on DBV Technologies and its competitors. According to the industry distribution chart, DBV Technologies ranks #999999 out of 959 companies in the Biotechnology industry.
Is DBV Technologies' OCF Margin % too high?
DBV Technologies' current OCF Margin % is 0.00%. Based on the distribution chart, DBV Technologies ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DBV Technologies has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #999999 out of 959 companies for OCF Margin %. This places DBV Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on DBV Technologies and its competitors. DBV Technologies's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (FRA:DBV) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. DBV Technologies' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For DBV Technologies (FRA:DBV), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
27GF Score

Get the complete analysis for FRA:DBV

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.77
Price